Effect of the Plasticizer DEHP in Blood Collection Bags on Human Plasma Fraction Unbound Determination for Alpha-1-Acid Glycoprotein (AAG) Binding Drugs
- 203 Downloads
Fraction unbound (fu) is a critical drug distribution parameter commonly utilized for modeling efficacious dosage and safety margin predictions. An over-estimation of fu for 13 chemically diverse small molecule drugs primarily bound to alpha-1-acid glycoprotein (AAG) in human plasma was discovered when in vitro results from our screening lab were compared to literature values. Di-(2-ethylhexyl) phthalate (DEHP), a plasticizer known to be used in the manufacture of blood collection bags, was extracted from plasma obtained through three common techniques that allowed contact with DEHP, and drug fu values in plasma from each collection method were estimated using the HTDialysis protein binding methodology. Additionally, fu of test compounds in plasma spiked with varying concentrations of DEHP (0–800 μM) was determined, and DEHP extractions were performed from plasma stored in Terumo bags over 7 days. Blood stored in Terumo bags, blood collected in Terumo bags, but immediately transferred to conical vials, and vacutainer-collected blood yielded DEHP concentrations of 300–1000 μM, 1–10 μM, and 0.1–2 μM, respectively. This finding corresponded with the fu of tested drugs in DEHP-spiked plasma increasing between 2- and 5-fold. Additionally, DEHP was discovered to leach from the Terumo bag, with concentrations increasing 10-fold over a 7-day test period. In summary, the presence of DEHP in commercially available blood collection bags confounds in vitro fu estimation for drugs that bind primarily to AAG. It is recommended that vacutainer-collected human plasma, which contains negligible DEHP, be used for the most accurate estimation of fu in human plasma.
KEY WORDSalpha-1-acid glycoprotein equilibrium dialysis plasma protein binding plasticizer di-(2-ethylhexyl) phthalate (DEHP)
The authors would like to thank Will Plentl and team at ZenBio, Inc. for collecting and storing donated plasma under our specified experimental conditions, and Sabrina Giordano at BioreclamationIVT for information regarding plasma storage conditions.
- 1.Brown K, Hingorani G, Franklin R. An effective screening approach to assess the impact of α-1 acid glycoprotein binding on the fraction unbound of a drug. Poster session presented at: 17th Annual ISSX Meeting; 2011. Oct 16–20; Atlanta GA.Google Scholar
- 8.Leetz A. Frace first EU country to ban the use of DEHP in paediatrics, neonatology maternity wards in Hospitals Health Care Without Harm Europe. 2012; Dec 13.Google Scholar
- 11.Zamek-Gliszczynski M, Ruterbories J, Ajamie R, Wikremsinhe E, Pothuri L, Rao MVS, et al. Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J Pharm Sci. 2011;100(6):2498–507.CrossRefGoogle Scholar
- 12.D. Feigal. PVC devices containing the Plasticzier DEHP. In: FDA Public Health Notification. U.S. Food and Drug Administration. 2002. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062182.htm. Accessed 25 Aug 2016.
- 13.Shah D, Burgess J. A simple, fast, and reliable LC-MS/MS method for determination and quantification of phthalates in distilled beverages. In: Application Notes. Waters Corporation. 2015. http://www.waters.com/webassets/cms/library/docs/720005403en.pdf. Accessed 29 Apr 2016.
- 16.Di L, Kerns EH. Application of pharmaceutical profiling assays for optimization of drug-like properites. Curr Opin Drug Discov Dev. 2005;8(4):495–504.Google Scholar
- 22.Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, Heald D. From preclinical to human—prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos. 2012;33(2):111–21. https://doi.org/10.1002/bdd.1782.CrossRefPubMedGoogle Scholar
- 23.Drugs@FDA: FDA Approved Drug Products [Internet]. Silver Spring: U.S. Food and Drug Administration; c1996. Xanax; (revised 2011 Mar; cited 2018 Apr 16; 44 p.). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018276s044,021434s006lbl.pdf.